Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole.
about
Voriconazole therapeutic drug monitoring.Epidemiology of invasive candidiasis: a persistent public health problemCanadian clinical practice guidelines for invasive candidiasis in adults.Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centersComparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropeniaComparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agentsProgress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazoleAnidulafungin in the treatment of invasive fungal infections.Nosocomial fungal infections: epidemiology, diagnosis, and treatment.In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.When primary antifungal therapy fails.In Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen.Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.Invasive mold infections: recent advances in management approaches.Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.Antifungal drug resistance among Candida species: mechanisms and clinical impact.Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections.Activity of fluconazole and its Cu(II) complex towards Candida species.[Strategies for antifungal treatment failure in intensive care units].Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by useUse of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009).Clinical significance of azole antifungal drug cross-resistance in Candida glabrata.Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.
P2860
Q24542411-B26D1AD0-96B3-4634-9C01-29163225340AQ29616758-500E59FD-D697-4F34-AC3E-107986675711Q34237335-18C2F7A6-859F-4D13-9822-65DD7FA0667BQ35073043-09F90422-02FD-4359-AB91-7997F0228B88Q35140151-3254FC59-1AE2-4C6F-8B5E-5C2C05292E74Q35647785-A8F4D235-904C-4DC2-8408-406215C0D3F9Q35690629-FFAC99E2-C8D1-4872-A43D-AE5C0F971509Q36172242-6C036403-B123-488F-BDA6-721A811FA671Q36491819-C6EF1B52-311F-4DA9-8E63-1FB90AFB5D74Q36505508-B29FB78D-9DF8-49D6-9B4C-6A9D3409F3B0Q36521993-4561D685-B287-4B6A-8E2E-F7762F33F6BDQ36822941-6005F250-D0A9-4B5B-A905-947B82361362Q36825717-D184C481-0D46-47EF-9879-3E776880F6C4Q37036173-E201A6C7-9A3B-4AA4-AA23-87851A80224CQ37141191-811C32CE-2567-4616-A7B2-806AA673F798Q37160845-29FEE87D-3134-4EDB-86BC-38CD43493AE9Q37374850-0B654064-4FD3-47E3-B70D-876AFD21B3B2Q37428946-ABE10A34-0745-4EFF-99E0-760335D8DBF3Q37621550-B36CF9A1-E179-45C1-A8C0-6E161D0821B7Q38511946-0A80CA08-D08F-4A09-8C6B-3256F4F500F4Q39899742-7812CFF7-D57E-48DA-88CC-A8B6A4004B8CQ40189236-E2A8300F-D6F0-4CB6-966A-19B390964F3FQ40673716-3557BCD9-CCF0-42BC-963F-BA12D12202E2Q41010354-7DF89EE2-332F-4934-8365-5A67E67911A1Q41969487-04CA8045-47B6-42EA-8749-F314F924BCEBQ42071108-9307E7F6-680B-4337-9B65-E96D14505A79Q42169461-0CBD1356-342B-4857-A6FC-86316E3D4651Q42408609-4508F21D-91CE-40A6-BEC4-A2824FBE5156Q42625550-F09B4CBD-508B-4C94-A815-BD2713C43620Q46876288-0C920779-AECB-4844-92D3-99936E4C6A02
P2860
Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Candida glabrata fungemia in t ...... oriconazole after fluconazole.
@en
Candida glabrata fungemia in t ...... oriconazole after fluconazole.
@nl
type
label
Candida glabrata fungemia in t ...... oriconazole after fluconazole.
@en
Candida glabrata fungemia in t ...... oriconazole after fluconazole.
@nl
prefLabel
Candida glabrata fungemia in t ...... oriconazole after fluconazole.
@en
Candida glabrata fungemia in t ...... oriconazole after fluconazole.
@nl
P2093
P1433
P1476
Candida glabrata fungemia in t ...... oriconazole after fluconazole.
@en
P2093
Barbara D Alexander
Gwynn D Long
Jackie L Miller
Wiley A Schell
P304
P356
10.1097/01.TP.0000173771.47698.7B
P577
2005-09-01T00:00:00Z